Table 3.

Treatment for COVID-19

1	Antiviral drug (anti-SARS-Cov-2 action)
	1) Favipiravir (Abigan): RNA polymerase inhibitor. Influenza drug
	2) Remdesivir (Beckley): RNA polymerase inhibitor. Ebola bleeding drug. Special approval on May 7, 2020 in Japan
	3) Ivermectin (Stromectol): Macrolide antibiotic. Anthelmintic
	4) Hydroxychloroquine (Plaquenil): Antimalarial drug. SLE therapeutic drug
	5) Lopinavir/ritonavir combination drug (Kaletra): Protease inhibitor. HIV treatment
	6) Ciclesonide (Alvesco): Inhaled steroid asthma treatment. Has anti-SARS-CoV-2 action
	7) Nafamostat (Futhan, Coahibitor, etc.): Serine protease inhibitor. A therapeutic drug for DIC and pancreatitis in Japan. Inhibits the serine protease TMPRSS2
	8) Camostat (Foipan): A serine protease inhibitor. A remedy for pancreatitis in Japan. The inhibitory effects on TMPRSS2 are weaker than those of nafamostat
	9) Vaccine: Under development by many companies
	10) Convalescent plasma treatment: Expected therapeutic effects through antibody obtained from the serum of convalescent patients
2	Treatment of cytokine storm
	1) Tocilizumab, salilumab: anti-IL-6 receptor antibody
	2) Anakinra: IL-1 receptor antagonist
	3) JAK inhibitor
	4) Anti-GM-CSF drug
	5) Anti-complement antibody
	6) Anti-TNF drug
	7) Dexamethasone
	8) Blood purification therapy using a cytokine adsorption column
3	Antithrombotic therapy
	1) Unfractionated heparin (+ AT preparation: DIC with AT activity ≤ 70% is covered by insurance)
	2) Low molecular weight heparin (+ AT preparation: as above)
	3) DOAC (anti-Xa drug insurance coverage is venous thromboembolism)
	4) Thrombomodulin preparation (insurance coverage is DIC)
	5) Argatroban (Insurance coverage is for acute cerebral infarction, chronic arterial occlusion, HIT, etc.)
	6) tPA: Reports have described both systemic administration and inhalation

The above is described regardless of insurance coverage. Please confirm the insurance coverage in the package insert